Posterior Reversible Encephalopathy Syndrome

Weihai Municipal Hospital

Prognostic Observation of Posterior Reversible Encephalopathy Syndrome

Bo Gao, MD

Associate Chief Physician

Yantai Yuhuangding Hospital

University of Southern California

After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.

Chronic Kidney Disease

Anemia

Complication of Peritoneal Dialysis

Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity

Renogen

Department of Adult Nephrology; National Kidney and Transplant Institute

The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients

A Study on the Effect of Hemoglobin Level and the Vascular Reactivity Using th Generic Erythropoeitin Alpha (Renogen) on Incident Peritoneal Dialysis Patients

We will measure the baseline hemoglobin level and the status of the flow mediated-dilatation of the brachial artery. We will assess the status of hemoglobin level and the flow mediated dilatation at the end of the study and show assess its correlation.

We will assess if the erythropoietin alpha (Renogen) is effective in maintaining the target hemoglobin level of the study every month. Included in the assessment are the abrupt increase or decrease of the hemoglobin level

We will monitor the average baseline blood pressure of the patient at baseline. During the study period of 3 months, blood pressure of the patients will also be monitored if there is increase of blood pressure from baseline

Romina A. Danguilan

Doctor

National Kidney and Transplant Institute, Philippines

Disorders Associated With Peritoneal Dialysis

Measurement of peritoneal protein loss level with use of ACEIs

Group using angiotensin converting enzyme inhibitor

Measurement of peritoneal protein loss level without usage of ACEIs

hypertensive encephalopathy/albümin

Prognostic Observation of Posterior Reversible Encephalopathy Syndrome

The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients

Effects of Aceis on Peritoneal Protein Loss and Solute Transport in pd Patients

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı